📸 Community Results — Not Clinical Trials
Community-reported results. Individual results vary. Not from clinical trials.
🔑 What Real Users Report
- Average weight loss in community reports: 15–25 lbs in the first 8 weeks at low doses
- Most users hit a strong appetite suppression effect within 3–5 days of first injection
- Nausea is the most common complaint — significantly reduced when titrating slowly
- GLP-1 fatigue ("retatrutide tiredness") is real but typically fades after 2–3 weeks
- Results at 24 weeks in trials: up to 24.2% body weight loss — the highest recorded for any weight loss drug
- Users who stacked with MOTS-c report better energy and muscle preservation during the cut
Retatrutide has been circulating in research communities since 2023, when the Phase 2 NEJM trial dropped numbers that nobody had seen before — 24% body weight loss at 48 weeks, nearly double what semaglutide (Ozempic) achieves. Since then, a large community of self-experimenters has been running it and reporting results online.
This article compiles what actual users are experiencing: timelines, weight loss numbers, side effect management, and the honest comparison to semaglutide and tirzepatide. Not just trial data — real-world use.
The Clinical Baseline: What Trials Actually Showed
Community-reported results. Individual results vary based on dose, diet, and protocol.
The Phase 2 trial (published NEJM, 2023) enrolled 338 adults with obesity. At the 12mg/week dose, participants lost an average of 24.2% of body weight at 48 weeks. For context:
- Semaglutide (Ozempic 2.4mg) averages ~15% at 68 weeks in STEP trials
- Tirzepatide (Mounjaro/Zepbound) averages ~20–22% at 72 weeks in SURMOUNT trials
- Retatrutide hit 24.2% in fewer weeks — at its Phase 2 dose (not even fully optimized yet)
The glucagon receptor agonism is what separates it. GLP-1 drugs suppress appetite. Tirzepatide adds GIP for better insulin sensitivity. Retatrutide adds glucagon on top, which directly accelerates fat burning and energy expenditure — independent of eating less. That's the mechanism behind the faster, more complete fat loss.
Real User Reviews: What People Are Reporting
Week-by-Week Timeline (Composite from Community Reports)
| Week | Typical Experience | Avg Weight Change |
|---|---|---|
| 1–2 | Strong appetite suppression hits by day 3–5. Nausea most common in this window. Some report fatigue. | −3 to −6 lbs |
| 3–4 | Nausea usually subsides. Energy improves. Food noise drops dramatically — "I forgot to eat" is the #1 comment. | −7 to −12 lbs cumulative |
| 5–8 | Steady loss continues. Most users report losing 1.5–2.5 lbs/week without tracking calories. | −15 to −25 lbs cumulative |
| 9–16 | Rate slows slightly as body adapts. Muscle preservation becomes a concern — users stack MOTS-c or protein-focused. Still consistent loss. | −25 to −40 lbs cumulative |
| 17–24 | Those who continue see additional loss. Plateau-busters: dose increase, short diet breaks, exercise add-in. | −40 to −55 lbs cumulative at high end |
What Users Love
"Food Noise Goes Quiet"
The most consistently reported effect — and the one users find most surprising. The constant mental chatter about food, cravings, and snacking essentially stops. Users describe it as "the fridge doesn't call me anymore."
Speed of Results
Faster than semaglutide at equivalent timepoints. Users who switched from Ozempic to retatrutide commonly report breaking through plateaus within 2–3 weeks of switching.
Metabolic Markers Improve
Community members tracking bloodwork report significant drops in fasting glucose, triglycerides, and LDL alongside weight loss — consistent with the trial data on cardiometabolic effects.
Better Muscle Retention Than Expected
Some users expected GLP-1-style muscle loss — instead they report retaining muscle better than on semaglutide alone, possibly due to glucagon's metabolic effects. Stacking with MOTS-c amplifies this.
Common Complaints & Side Effects
| Side Effect | Frequency | What Users Do |
|---|---|---|
| Nausea | Very common (especially weeks 1–3) | Start at 0.5–1mg, titrate slowly over 4+ weeks. Take injection at night. Ginger, small meals. |
| Fatigue / tiredness | Common in weeks 1–4 | Usually resolves. Stay hydrated. Don't cut calories too aggressively early. |
| Muscle cramps | Moderate | Electrolytes — potassium and magnesium specifically. Common during rapid weight loss. |
| Hair thinning (telogen effluvium) | Moderate (3–4 months in) | Ensure adequate protein (1g+/lb lean mass). Often temporary as body adjusts. |
| Heart rate increase | Common, mild | Glucagon effect — raises resting HR 5–15bpm. Usually not symptomatic. Monitor if cardiac history. |
| Injection site reactions | Occasional | Rotate sites. Let vial reach room temp before injecting. |
| Constipation | Common (GI motility slowing) | Fiber, magnesium glycinate, hydration. More common than diarrhea unlike semaglutide. |
Retatrutide vs Semaglutide — What Switchers Report
A common pattern: someone plateaus on Ozempic after 3–4 months and switches to retatrutide. The reports are consistent:
- Plateau broken within 2–3 weeks of switching in most reports
- Appetite suppression noticeably stronger — users describe semaglutide as "training wheels" in comparison
- More energy on retatrutide than semaglutide (glucagon's metabolic effect)
- More nausea initially — the triple mechanism hits harder out of the gate
- Faster weight loss — most switchers report 1.5–3× their semaglutide rate in the first 4–6 weeks
| Factor | Semaglutide (Ozempic/Wegovy) | Retatrutide |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP + glucagon agonist |
| Avg weight loss (trial) | ~15% at 68 weeks | ~24% at 48 weeks |
| Appetite suppression | Strong | Very strong |
| Side effect profile | Nausea, diarrhea | Nausea, constipation, HR increase |
| Energy levels | Neutral to negative | More energizing (glucagon effect) |
| FDA status | Approved (Wegovy) | Phase 3 (research use only) |
| User reviews | More gradual, mild | Faster, stronger, more noticeable |
Before & After: Community Examples
📊 Typical Before/After Profiles (Community Composites)
Profile 1 — 8 weeks, 2mg/week: 38M, 245 lbs start → 221 lbs end. No calorie counting, same exercise. Nausea in week 1 only.
Profile 2 — 16 weeks, titrated to 4mg: 44F, 198 lbs → 163 lbs. Stacked MOTS-c from week 8. Reports strong energy and no muscle loss on DEXA.
Profile 3 — 24 weeks, 6mg plateau: 52M, 310 lbs → 238 lbs (72 lbs). Had plateaued on tirzepatide before switching. Called it "the upgrade."
Profile 4 — 12 weeks, 3mg: 31F, 165 lbs → 149 lbs. Primary goal was body recomposition. Reports pants down 2 sizes despite only 16 lbs scale change — significant body composition shift.
Dosage Protocol That Users Are Running
| Week | Dose | Notes |
|---|---|---|
| 1–2 | 0.5–1mg weekly | Gauge tolerance. Expect nausea. |
| 3–4 | 1–2mg weekly | Increase if tolerating well. |
| 5–8 | 2–3mg weekly | Most users find sweet spot here. |
| 9–16 | 3–5mg weekly | Maintenance dose for ongoing fat loss. |
| 16+ | 4–6mg weekly (some up to 8mg) | Higher doses reserved for those tolerating well with plateaus. |
Popular Retatrutide Stacks
- Retatrutide + MOTS-c: The most popular combo in the community. MOTS-c improves mitochondrial function and muscle insulin sensitivity — helps preserve muscle mass and energy during aggressive fat loss.
- Retatrutide + BPC-157: Some users add BPC-157 for gut comfort, especially to reduce the GI side effects in the early weeks.
- Retatrutide + GHK-Cu: Used by anti-aging-focused users. GHK-Cu addresses the skin laxity that can come with rapid weight loss.
Where to Get Retatrutide for Research
Retatrutide is currently in Phase 3 trials and not yet FDA approved. It's available as a research peptide from domestic US suppliers. Ascension Peptides carries it as R-30 (30mg vial) — independently third-party tested with batch COAs, US domestic shipping. It's what most of the community uses as a trusted source.
For full sourcing guidance, protocol tips, and what to avoid, see the retatrutide where to buy guide.